CN103814046B - 针对内体/溶酶体酶的抑制剂 - Google Patents

针对内体/溶酶体酶的抑制剂 Download PDF

Info

Publication number
CN103814046B
CN103814046B CN201280039856.9A CN201280039856A CN103814046B CN 103814046 B CN103814046 B CN 103814046B CN 201280039856 A CN201280039856 A CN 201280039856A CN 103814046 B CN103814046 B CN 103814046B
Authority
CN
China
Prior art keywords
conjugate
cystatin
protease inhibitor
inhibitor
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280039856.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103814046A (zh
Inventor
科林·沃茨
桑德尔·范卡斯特伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Dundee
Original Assignee
University of Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Dundee filed Critical University of Dundee
Publication of CN103814046A publication Critical patent/CN103814046A/zh
Application granted granted Critical
Publication of CN103814046B publication Critical patent/CN103814046B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8142—Aspartate protease (E.C. 3.4.23) inhibitors, e.g. HIV protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280039856.9A 2011-08-15 2012-08-15 针对内体/溶酶体酶的抑制剂 Expired - Fee Related CN103814046B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1114017.5 2011-08-15
GBGB1114017.5A GB201114017D0 (en) 2011-08-15 2011-08-15 Inhibitors against endosomal/ysosomal enzymes
PCT/GB2012/000660 WO2013024243A1 (en) 2011-08-15 2012-08-15 Inhibitors against endosomal/lysosomal enzymes

Publications (2)

Publication Number Publication Date
CN103814046A CN103814046A (zh) 2014-05-21
CN103814046B true CN103814046B (zh) 2017-05-17

Family

ID=44764498

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280039856.9A Expired - Fee Related CN103814046B (zh) 2011-08-15 2012-08-15 针对内体/溶酶体酶的抑制剂

Country Status (6)

Country Link
US (1) US9050374B2 (enExample)
EP (1) EP2744821B1 (enExample)
CN (1) CN103814046B (enExample)
GB (1) GB201114017D0 (enExample)
IN (1) IN2014DN01822A (enExample)
WO (1) WO2013024243A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6907188B2 (ja) 2015-08-13 2021-07-21 ダイアックス コーポレーション 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管
MA55947A (fr) 2016-08-11 2022-03-23 Intrabio Ltd Compositions pharmaceutiques et utilisations dirigées vers des troubles d'entreposage lysosomial
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323063A1 (en) 1998-03-26 1999-09-30 University Of Dundee Use of inhibitors of mammalian asparaginyl endopeptidase for therapy of autoimmune disease
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
半胱氨酸蛋白酶抑制剂C在肿瘤研究中的进展;王蕾等;《检验医学》;20080331;第23卷(第23、期);199-201 *

Also Published As

Publication number Publication date
EP2744821A1 (en) 2014-06-25
US9050374B2 (en) 2015-06-09
US20140308318A1 (en) 2014-10-16
IN2014DN01822A (enExample) 2015-05-15
CN103814046A (zh) 2014-05-21
EP2744821B1 (en) 2016-12-07
GB201114017D0 (en) 2011-09-28
WO2013024243A1 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
US20240140999A1 (en) Stabilized peptide-mediated targeted protein degradation
JP6249949B2 (ja) 薬物動態特性の改善されたコンプスタチンアナログ
JP2018506509A (ja) 細胞透過性Ｂｃｌ−ｘＬ阻害剤との抗体薬物コンジュゲート
AU2019207534B2 (en) Proteinaceous molecules and uses therefor
AU2017283820B2 (en) Neural thread peptide for preventing or reducing the progression of prostate cancer
EP3046570A1 (en) Compositions and methods for protecting the kidney from ischemia reperfusion injury
CN114621318A (zh) 用于炎症和纤维化的肽治疗
CN103814046B (zh) 针对内体/溶酶体酶的抑制剂
CN115996942A (zh) 靶向巨噬细胞的肽及其缀合物、组合物和用途
AU2007220307A1 (en) Cathepsin propeptide and uses thereof
CA2906775A1 (en) Bh4 stabilized peptides and uses thereof
US20220354957A1 (en) Peptides targeting macrophages, and conjugates, compositions, and uses thereof
WO2004106371A1 (en) Livin-derived peptides, compositions and uses thereof
US20230405134A1 (en) Novel protac chimeric compound, and pharmaceutical composition comprising same for preventing, ameliorating, or treating diseases through target protein degradation
JP6768140B2 (ja) 急性尿閉の発生を予防または低減させる方法
KR102017973B1 (ko) 항-b형 간염 바이러스 x 단백질 폴리펩티드 약제
CA2903608C (en) Treatment of endometriosis, angiogenesis and/or endometrial lesion growth
RU2780890C2 (ru) Способ лечения доброкачественной гиперплазии предстательной железы с помощью антибиотиков
CA3093763A1 (en) Method of treating benign prostatic hyperlasia with antibiotics
WO2005009457A1 (en) Rdp58 compositions and methods for inhibiting vascularization of cell populations
AU2017214761A1 (en) Proteinaceous compounds and uses therefor
KR20230024838A (ko) 종양 유래 소포를 붕괴시키는 항암 면역치료용 펩타이드 및 이의 용도
JP2022530823A (ja) がん治療のためのペプチド誘導体とそのコンジュゲート
CN116964074A (zh) 调节vegf的肽
WO2007022534A1 (en) Preparation of a peptide compound (norapro-2002) and its use for the activation of protein phosphatase-2a enzymes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170517

Termination date: 20180815

CF01 Termination of patent right due to non-payment of annual fee